In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
The activities of anidulafungin and caspofungin against Candida glabrata were evaluated. MICs, 50% inhibitory concentrations (IC(50) values), and IC(90) values for anidulafungin were lower than those for caspofungin for 16 of 18 strains tested. Anidulafungin has potent in vitro activity against C. glabrata that is maintained against isolates with elevated caspofungin MICs.
Cota
Jason
J
University of Texas at Austin College of Pharmacy, UTHSCSA, Clinical Pharmacy, MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
Carden
Michael
M
Graybill
John R
JR
Najvar
Laura K
LK
Burgess
David S
DS
Wiederhold
Nathan P
NP
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000494:pharmacology*; D041221:Candida glabrata / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology; D000077336:Caspofungin; D003124:Colorimetry; D004305:Dose-Response Relationship, Drug; D025141:Drug Resistance, Fungal; D054714:Echinocandins; D006801:Humans; D007700:Kinetics; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology*; D013778:Tetrazolium Salts
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D013778:Tetrazolium Salts; C059087:2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide; D000077612:Anidulafungin; D000077336:Caspofungin